News

Neuromyelitis optica spectrum disorder (NMOSD) may begin to manifest as uncontrollable nausea, vomiting, or hiccups — a condition referred to as area postrema syndrome (APS) — as described in a report of four patients in China. Because these symptoms can overlap with those of other diseases, their occurrence…

A European Medicines Agency (EMA) committee has recommended that Ultomiris (ravulizumab) be approved to treat adults with neuromyelitis optica spectrum disorder (NMOSD) who are positive for antibodies against aquaporin-4 (AQP4). The recommendation, from the EMA’s Committee for Medicinal Products for Human Use (CHMP), will now be reviewed by the European…

Symptoms related to the autonomic nervous system, which controls automatic bodily function, have a significant impact on the quality of life of people with neuromyelitis optica spectrum disorder (NMOSD), according to a questionnaire-based study. All patients in the study experienced some autonomic system-related symptoms, or autonomic dysfunction, and most…

People who are younger at the onset of neuromyelitis optica spectrum disorder (NMOSD) and those with multiple organ involvement at the first attack by the disease have a higher risk of relapse during treatment with traditional immunosuppressants, a study showed. A reduction in the levels of antibodies against…

Eye scans of people with neuromyelitis optica spectrum disorder (NMOSD) revealed they may have a thicker retina — the eye’s light-detector — and more blood vessels than people with myelin oligodendrocyte glycoprotein antibody disease (MOGAD). That’s according to a study in which researchers used two noninvasive imaging techniques,…

A global Phase 4 clinical trial of Enspryng (satralizumab), approved to treat the most common form of neuromyelitis optica spectrum disorder (NMOSD), is enrolling newly diagnosed and other patients who could not or did not take part in Phase 3 trials of the therapy. In addition to people new…

Uplizna (inebilizumab) reduces the formation of asymptomatic lesions in the nerves that connect the eyes to the brain in people with neuromyelitis optica spectrum disorder (NMOSD), according to a new data analysis from the Phase 2/3 N-MOmentum trial. Asymptomatic, or subclinical, lesions are those that don’t lead to…

For one in three people with neuromyelitis optica spectrum disorder (NMOSD), bad days — marked by high levels of debilitating symptoms — are more common than good days. Patients who are more comfortable talking with their doctors about their symptoms reported fewer bad days and greater treatment…

Ad Scientiam is developing new digital biomarkers of neuromyelitis optica spectrum disorder (NMOSD) that may allow continuous and remote monitoring of patients’ symptoms over time. The Paris-based software company announced the program launch along with a similar one for people with generalized myasthenia gravis, another rare autoimmune…

The annual prevalence of neuromyelitis optica spectrum disorder (NMOSD) in the U.S. is considerably higher than previously estimated, affecting about nine out of every 100,000 people, according to a study that analyzed 2021 electronic health records. The data also showed that the disease is more than twice as common…